Thalidomide for chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44663253

Enrollment

Registered

2003-09-12

Start date

2000-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular: Heart failure Circulatory System Heart failure

Interventions

Randomised controlled trial comparing a) thalidomide and b) placebo 100 mg twice daily for 12 weeks in random order. End points will be measured at baseline, crossover point and end of study. Added

Eligibility

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Secondary

Measure	Time frame
Not provided at time of registration	—

Primary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026